MesenSistem-EB Trial: Systemic MSC Therapy Outcomes in Epidermolysis Bullosa

A 12-month Phase I/II clinical trial conducted by Rocío Maseda evaluated systemic haploidentical mesenchymal stem cell therapy in nine children with recessive dystrophic epidermolysis bullosa. The dataset likely contains safety, clinical, patient-reported outcomes, systemic inflammatory mediator levels, and peripheral blood immune profiles. The data is available under a CC-BY-4.0 license and was last updated in May 2026.

Use Cases

• Analyze correlations between clinical outcomes and biomarker dynamics based on sCD40L and MCP1 levels mentioned in the description
• Model patient response classification based on reported improvements in disease severity, pruritus, or inflammation
• Investigate immune cell subset changes based on flow cytometry data for circulating myeloid and lymphoid compartments
• Evaluate safety profiles of systemic MSC therapy based on reported adverse event data

Strengths

• Data originates from a defined Phase I/II clinical trial with nine recruited patients and eight completers
• Includes multiple assessment types: safety, clinical outcomes, patient-reported outcomes, inflammatory mediators, and immune profiles
• Longitudinal data collected over a 12-month study period

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is 1.9 MB, suggesting a relatively small scale

Provenance

Source

figshare

Collection Method

Data collected from a single-center, open-label clinical trial (NCT04153630)

Time Range

Study period spanned 12 months

Freshness

Last updated 2026-05-05 04:13:33; freshness should be verified